ESR1 and breast cancer: The same combination of Eri plus pembrolizumab was also tested in patients with metastatic, estrogen receptor–positive (ER+) BC (which are mainly cold tumors) (10) in a phase II trial (37) that showed no additional benefit of adding pembrolizumab compared with Eri alone.